Proprietary Hyper-crosslinked Carbohydrate Polymer (HCCP) is used to support cartilage formation in defect sites. It promotes chondrocyte growth and extracellular matrix production within a biocompatible matrix, offering a next-generation alternative to microfracture and autologous chondrocyte implantation.

The U.S. market exceeds $1 billion, with over 200,000 procedures annually. Successful prototyping and feasibility studies are complete, supported by in vitro chondrocyte culture and histology data.

Projected peak sales are $200 million per year.